Page last updated: 2024-12-11

1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one, also known as **nitrofurazone**, is an **antibacterial agent** with a long history of use in human and veterinary medicine.

Here's a breakdown of its structure and importance:

**Structure:**

* **Nitrofuran moiety:** The 5-nitrofuran-2-yl group is the core structural feature responsible for nitrofurazone's antimicrobial activity. It acts as an electron acceptor, interfering with bacterial metabolism.
* **Piperazine ring:** The 4-methylpiperazin-1-yl group contributes to the molecule's overall shape and solubility, influencing its absorption and distribution in the body.
* **Enone system:** The prop-2-en-1-one moiety, also known as an enone, is a conjugated double bond system, which contributes to the molecule's stability and potential interactions with biological targets.

**Importance in Research:**

* **Broad-spectrum activity:** Nitrofurazone exhibits broad-spectrum antibacterial activity, effective against a wide range of Gram-positive and Gram-negative bacteria.
* **Topical applications:** Primarily used topically for wound and burn infections, nitrofurazone has been particularly effective in treating superficial skin infections.
* **Mechanism of action:** Research into the precise mechanism of action of nitrofurazone is ongoing, but it is believed to interfere with bacterial DNA synthesis and other essential metabolic processes.
* **Antibacterial resistance:** Although nitrofurazone has shown effectiveness against many bacteria, resistance can develop. Researchers continue to explore its potential uses and investigate new derivatives that might overcome resistance issues.
* **New formulations:** Researchers are exploring new formulations of nitrofurazone to improve its delivery, efficacy, and safety.

**Research Focus:**

Current research focuses on:

* **Developing new derivatives:** Scientists are synthesizing and studying new derivatives of nitrofurazone to enhance its antimicrobial properties, increase its stability, and overcome resistance issues.
* **Investigating mechanisms of action:** Further understanding of the mechanisms of action of nitrofurazone will enable the development of new and more effective antibacterial agents.
* **Exploring alternative applications:** Researchers are investigating the potential of nitrofurazone in other areas, such as antifungal or antiviral applications.

**Overall, nitrofurazone remains a valuable tool for research into antibacterial drug development and treatment strategies.** Its unique structure and broad-spectrum activity continue to inspire the exploration of new and improved antimicrobial therapies.

1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one: a p73 protein-stimulating compound that restores p53 signaling; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5356520
CHEMBL ID1979662
SCHEMBL ID17071991
SCHEMBL ID17654893
MeSH IDM000612902

Synonyms (37)

Synonym
nsc59984
mls000737358 ,
nsc-59984
smr000528276
(e)-1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one
1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one
HMS2885J20
(e)-1-(4-methyl-1-piperazinyl)-3-(5-nitro-2-furanyl)-2-propen-1-one
cid_5356520
bdbm96260
(e)-1-(4-methylpiperazino)-3-(5-nitro-2-furyl)prop-2-en-1-one
S8106
CS-5382
HY-19726
CHEMBL1979662
AC-32965
803647-40-7
nsc 59984
SCHEMBL17071991
J-690353
n-[1,3-dimethyl-2-oxo-6-(1-pyrrolidinyl)-2,3-dihydro-1h-benzimidazol-5-yl]-2-methoxybenzamide
SCHEMBL17654893
EX-A776
AKOS030525998
nsc59984, >=98% (hplc)
mfcd29905462
BCP16647
BS-18159
A13413
EN300-21685041
(2e)-1-(4-methylpiperazin-1-yl)-3-(5-nitrofuran-2-yl)prop-2-en-1-one
CCG-267098
nsc59984,nci59984
(2e)-1-(4-methyl-1-piperazinyl)-3-(5-nitro-2-furyl)-2-propen-1-one
EN300-245475
2643927-71-1
Z116302242
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency25.11890.177814.390939.8107AID2147
Nrf2Homo sapiens (human)Potency5.68090.09208.222223.1093AID624171; AID651593
glp-1 receptor, partialHomo sapiens (human)Potency3.98110.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency10.00000.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency12.99000.004110.890331.5287AID504466
TDP1 proteinHomo sapiens (human)Potency11.89050.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency19.95260.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency17.78280.100022.9075100.0000AID485364
Smad3Homo sapiens (human)Potency11.22020.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency11.22020.00018.4406100.0000AID720580
P53Homo sapiens (human)Potency22.38720.07319.685831.6228AID504706
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency18.35640.00419.984825.9290AID504444
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency25.11890.425612.059128.1838AID504891
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency23.35070.00798.23321,122.0200AID2546; AID2551
gemininHomo sapiens (human)Potency20.59620.004611.374133.4983AID624296
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency12.58930.00419.962528.1838AID2675
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency6.30960.025911.239831.6228AID602313
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
exodeoxyribonuclease V subunit RecBEscherichia coli str. K-12 substr. MG1655IC50 (µMol)39.49300.10000.10000.1000AID652151
exodeoxyribonuclease V subunit RecCEscherichia coli str. K-12 substr. MG1655IC50 (µMol)39.49300.10000.10000.1000AID652151
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's6 (66.67)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.25 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]